兩連板的仟源醫藥(300254.SZ):公司及子公司4個藥品擬中標第三批集採
格隆匯 8 月 21日丨仟源醫藥(300254.SZ)公告,公司股票交易價格於2020年8月19日、8月20號、8月21日連續三個交易日收盤價格漲幅偏離值累計超過20%,根據深圳證券交易所的有關規定,屬於股票交易異常波動的情況。
公司之子公司江蘇嘉逸醫藥有限公司於近日收到國家藥品監督管理局簽發的化學藥品“阿哌沙班片”的《藥品註冊批件》,同時原料藥阿哌沙班也獲國家藥監局關聯審評通過。該產品主要用於髖關節或膝關節擇期置換術的成年患者,預防靜脈血栓栓塞事件(VTE)。
2020年8月20日,公司及子公司浙江海力生製藥有限公司、江蘇嘉逸醫藥有限公司已通過仿製藥質量和療效一致性評價的藥品鹽酸氨溴索分散片、鹽酸氟西汀膠囊、鹽酸坦索羅辛緩釋膠囊和阿哌沙班片參加了聯合採購辦公室組織的第三批全國藥品集中採購投標工作。根據聯採辦發佈的全國藥品集中採購擬中選結果公示,上述藥品均擬中標本次集中採購。公司已與聯合採購辦公室簽訂了《全國藥品集中採購擬中選品種備忘錄》。
公司董事會確認,除前述事項外,本公司目前沒有任何根據《深圳證券交易所創業板股票上市規則》規定應予以披露而未披露的事項或與該事項有關的籌劃、商談、意向、協議等;董事會也未獲悉本公司有根據《深圳證券交易所創業板股票上市規則》的規定應予以披露而未披露的、對本公司股票及其衍生品種交易價格產生較大影響的信息;公司前期披露的信息不存在需要更正、補充之處。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.